RAD54L germline variants: rare; HR-pathway gene with limited clinical evidence. Included...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RAD54L-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | RAD54L germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | standard therapy, PARPi off-label (HRD context only) |
| Evidence summary | RAD54L germline variants: rare; HR-pathway gene with limited clinical evidence. Included in some HRR panels but no labeled indication. ESCAT IIIA / OncoKB Level 4. |
Notes
Risk allele status uncertain; counsel as variant of evolving significance. Cascade testing case-by-case.
Used By
No reverse references found in the YAML corpus.